ALZN Company Profile and Key Details

Alzamend Neuro Inc generated EPS of -$5.50 over the past year. Five-year average earnings growth is 30.49%. The latest quarter delivered EPS of -$0.74. The next quarter is forecast at -$0.53. Next year's EPS is expected at -$17.63. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $42.00 to $26.00. The high target offers 2400.0% upside. The low target suggests 1447.62% downside. The mean target is $36.67. This offers 2082.74% upside. Alzamend Neuro Inc earnings surprise history is a mixed track record. The quarter that ended July 22, 2026, missed forecasts by 10.45%. The prior quarter beat by 9.43%. Over the last six quarters, Apple has recorded several small beats. These include -83.19% in December 11, 2024.

Alzamend Neuro Inc has 4.83 million shares outstanding. The public float is 4.78 million shares, elevated short interest at 3.70% of float. This equals 176.57 thousand shares. The short ratio is 3.6 days. Institutional investors hold 2.48% of the float. Insiders own 2.68%. GUSTAFSON MARK holds 60.00 thousand shares, Jackman Stephan has 45.50 thousand shares and Katzoff David J has 5.54 thousand shares. Over the past six months, insider transactions show balanced activity. They sold 2.00 thousand shares across 1 transactions.

ALZN has shown sold momentum, gaining 3.86% over the past week and 9.01% over the past quarter, though year-to-date performance is up 32.97%. Short-term trend indicators are bullishly aligned (SMA20 6.39%, SMA50 -0.25%, SMA200 -18.35%). The stock’s 14-day RSI is 53.33 (neutral), while the ATR of 0.16 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -79.55% below its high and over 31.65% above its low. Average 10-day trading volume of 40.80 thousand shares is below the 3-month average of 144.70 thousand, indicating normal recent market interest.

The stock is currently mid-range between its 52-week high and low $0.84 and $2.68. With a market capitalization of about $6.39 million, Alzamend Neuro Inc is classified as a micro-cap and shows lower-than-market volatility (beta ~0.19). Key stats such as the average daily volume over the past year has been around 161.21 thousand shares, volume is running light vs its 52-week average. Headquartered in Atlanta, GA, Alzamend Neuro Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Stephan Jackman, the company employs approximately 6 people and listed since June 15, 2021. Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

Alzamend Neuro Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.21. This means the shares are trading above this model’s fair value.

Alzamend Neuro Inc trades at a P/E ratio of -0.59, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 7.81 trading at moderately above to book value. The P/FCF stands at -0.81, also above market averages.

Alzamend Neuro Inc (NASDAQ:ALZN) shares are up 32.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Alzamend Neuro Inc trading at a premium to the broader market with a P/E of -0.59. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $27.06, suggesting 1510.71% upside. Our AI forecast model points to short-term strength (8.93% over two weeks), a medium-term fall (-58.33% over three months), and a longer-term loss (-98.21% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Alzamend Neuro Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.93%, with price expected at $1.83 by September 23, 2026, within a range of $1.78 to $1.87 3-Month Outlook: Projected fall of -58.33%, reaching $0.70 by December 08, 2026, with a range of $0.57 to $0.83. 1-Year Outlook: Projected loss of -98.21%, with price at $0.03 by September 09, 2027, within a range of $0.00 to $2.70.